|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.10.25 - 12:03
|
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 (Business Wire)
|
|
|
Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing RegimenMIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland (Washington D.C. metro area) on Friday, November 7, 2025 at 11:30am ET.
HARMONi-A evaluated ivonescimab combined with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase i...
|
|
|
|
|
23.10.25 - 18:09
|
Agile Occupational Medicine Expands in the Central Valley With the Acquisition of California Occupational Physicians of Modesto (Business Wire)
|
|
|
Agile, California's second-largest independent occupational provider, now has 44 clinics throughout California and Arizona.COSTA MESA, Calif.--(BUSINESS WIRE)--#agileoccmed--Agile Occupational Medicine (“Agile”) announced today the acquisition of California Occupational Physicians, an occupational healthcare provider based in Modesto, CA. This acquisition marks a significant milestone for Agile, accelerating its California expansion strategy following its recent merger with Akeso Occupational Health. With the addition of this clinic, Agile now has 44 locations throughout California and Arizona.
“We are excited to partner with California Occupational Physicians and Dr. Richard Lind to serve employers and their employees in Modesto and the greater Central Valley,” said Peter Murray, CEO of Agile. “Our organizations share a vision of delivering the highest quality care to injured workers and supporting employers' occupational health. Together, I am confident we will deliver on that vision.”
Wit...
|
|
|
22.10.25 - 04:45
|
Research: CICC Cuts AKESOs TP to HKD184; Rating Kept Outperform (AAStocks)
|
|
|
AKESO (09926.HK) presented impressive interim analysis data from the HARMONi-6 study on October 19 at The Lancet & ESMO, according to a CICC research report.The company also revised the HARMONi-3 trial protocol to conduct an independent statistical analysis on primary endpoints based on histological types.In CICC's opini......
|
|
|
20.10.25 - 12:48
|
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 (Business Wire)
|
|
|
Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results
Expansion of Summit's Global Phase III Development Program Starts with Initiation of HARMONi-GI3, a New Study in 1L CRC: Summit to Initiate an Additional Set of Phase III Clinical Trials with Details to Come in Q1 2026
Ivonescimab with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy with Consistent Data across Regions
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40%, Median PFS of 11.14 Months, Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy, Median PFS 6.90 Months, in 1L Treatment of Patients with Squamous NSCLC in Phase III HARMONi-6 Study Conducted by Akeso in China
HARMONi-3 Global Phase III Study Analyses Will Be Split by Histology: Squamous NSCLC Cohort Expected to Complete Enrollment First Half of 2026 w...
|
|
|
20.10.25 - 09:00
|
China′s Akeso gets share boost as data shows cancer drug′s benefits (SCMP)
|
|
|
Shares of Chinese drug firm Akeso – likened by some Western media outlets to artificial intelligence start-up DeepSeek – rose after the company unveiled clinical-trial data showing that its lung-cancer drug outperformed a highly effective existing treatment.
The data showed that ivonescimab had “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said in a filing with the Hong Kong stock exchange on Monday. The drug, used along with......
|
|
|
|
|
|
|
15.10.25 - 13:03
|
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 (Business Wire)
|
|
|
Conference Call to be Held at 8:00am ETMIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data.
As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) which takes place from October 17–21, 2025, in Berlin, Germany. The presentation will take place on Sunday, October 19 during the Presidential Symposium from 4:30pm – 6:30pm CEST (10:30am – 12:30pm EDT).
HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with ti...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
